Revised response criteria for malignant lymphoma

被引：3825

作者：

Cheson, Bruce D.

Pfistner, Beate

Juweid, Malik E.

Gascoyne, Randy D.

Specht, Lena

Horning, Sandra J.

Coiffier, Bertrand

Fisher, Richard I.

Hagenbeek, Anton

Zucca, Emanuele

Rosen, Steven T.

Stroobants, Sigrid

Lister, T. Andrew

Hoppe, Richard T.

Dreyling, Martin

Tobinai, Kensei

Vose, Julie M.

Connors, Joseph M.

Federico, Massimo

Diehl, Volker

机构：

[1] Georgetown Univ Hosp, Div Hematol Oncol, Washington, DC 20007 USA

[2] Univ Cologne, Cologne, Germany

[3] Univ Iowa, Dept Nucl Med, Iowa City, IA USA

[4] British Columbia Canc Agcy, Dept Pathol, Vancouver, BC V5Z 4E6, Canada

[5] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

[6] Copenhagen Univ Hosp, Rigshosp, Dept Hematol & Oncol, Copenhagen, Denmark

[7] Stanford Univ, Div Oncol, Stanford, CA 94305 USA

[8] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA

[9] Hospices Civils Lyon, Dept Hematol, Lyon, France

[10] Univ Lyon 1, F-69365 Lyon, France

[11] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA

[12] Univ Amsterdam, Acad Med Ctr, Dept Hematol, NL-1105 AZ Amsterdam, Netherlands

[13] Oncol Inst So Switzerland, Dept Med Oncol, Lymphoma Unit, Bellinzona, Switzerland

[14] Northwestern Univ, Lurie Canc Ctr, Chicago, IL 60611 USA

[15] Univ Hosp Gasthuisberg, Dept Nucl Med, B-3000 Louvain, Belgium

[16] St Bartholomews Hosp, Canc Res UK Med Oncol Unit, London, England

[17] Univ Munich, Klinikum Grosshadern, Dept Med 3, D-8000 Munich, Germany

[18] Natl Canc Ctr, Hematol & Stem Cell Transplantat Div, Tokyo, Japan

[19] Univ Nebraska, Med Ctr, Hematol Oncol Sect, Omaha, NE USA

[20] Univ Modena & Reggio Emilia, Dipartimento Oncol & Ematol, Modena, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 05期

关键词：

D O I：

10.1200/JCO.2006.09.2403

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Methods The International Working Group response criteria (Cheson et al, J Clin Oncol 17: 1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [F-18] fluorodeoxyglucose-positron emission tomography ( PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations. Results New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided. Conclusion We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.

引用

页码：579 / 586

页数：8

共 51 条

[1] Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma [J].

Abrey, LE ;

Batchelor, TT ;

Ferreri, AJM ;

Gospodarowicz, M ;

Pulczynski, EJ ;

Zucca, E ;

Smith, JR ;

Korfel, A ;

Soussain, C ;

DeAngelis, LM ;

Neuwelt, EA ;

O'Neill, BP ;

Thiel, E ;

Shenkier, T ;

Graus, F ;

van den Bent, M ;

Seymour, JF ;

Poortmans, P ;

Armitage, JO ;

Cavalli, F .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5034-5043

[2] Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDC-PET) for accurate staging of Hodgkin's disease [J].

Bangerter, M ;

Moog, F ;

Buchmann, I ;

Kotzerke, J ;

Griesshammer, M ;

Hafner, M ;

Elsner, K ;

Frickhofen, N ;

Reske, SN ;

Bergmann, L .

ANNALS OF ONCOLOGY, 1998, 9 (10) :1117-1122

[3] Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial [J].

Bertoni, F ;

Conconi, A ;

Capella, C ;

Motta, T ;

Giardini, R ;

Ponzoni, M ;

Pedrinis, E ;

Novero, D ;

Rinaldi, P ;

Cazzaniga, G ;

Biondi, A ;

Wotherspoon, A ;

Hancock, BW ;

Smith, P ;

Souhami, R ;

Cotter, FE ;

Cavalli, F ;

Zucca, E .

BLOOD, 2002, 99 (07) :2541-2544

[4]

Buchmann I, 2001, CANCER, V91, P889

[5] Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma:: prevalence and scan interpretation [J].

Castellucci, P ;

Nanni, C ;

Farsad, M ;

Alinari, L ;

Zinzani, P ;

Stefoni, V ;

Battista, G ;

Valentini, D ;

Pettinato, C ;

Marengo, M ;

Boschi, S ;

Canini, R ;

Baccarani, M ;

Monetti, N ;

Franchi, R ;

Rampin, L ;

Fanti, S ;

Rubello, D .

NUCLEAR MEDICINE COMMUNICATIONS, 2005, 26 (08) :689-694

[6] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].

Cheson, BD ;

Horning, SJ ;

Coiffier, B ;

Shipp, MA ;

Fisher, RI ;

Connors, JM ;

Lister, TA ;

Vose, J ;

Grillo-López, A ;

Hagenbeek, A ;

Cabanillas, F ;

Klippensten, D ;

Hiddemann, W ;

Castellino, R ;

Harris, NL ;

Armitage, JO ;

Carter, W ;

Hoppe, R ;

Canellos, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253

[7]

Copie-Bergman C, 2005, ANN ONCOL, V16, P94

[8] Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma [J].

Copie-Bergman, C ;

Gaulard, P ;

Lavergne-Slove, A ;

Brousse, N ;

Fléjou, JF ;

Dordonne, K ;

de Mascarel, A ;

Wotherspoon, AC .

GUT, 2003, 52 (11) :1656-1656

[9] Utility of FDG-PET scanning in lymphoma by WHO classification [J].

Elstrom, R ;

Guan, L ;

Baker, G ;

Nakhoda, K ;

Vergilio, JA ;

Zhuang, H ;

Pitsilos, S ;

Bagg, A ;

Downs, L ;

Mehrotra, A ;

Kim, S ;

Alavi, A ;

Schuster, SJ .

BLOOD, 2003, 101 (10) :3875-3876

[10]

Foltz LM, 2004, BLOOD, V104, p853A

← 1 2 3 4 5 6 →